debug_export.json

{
  "type": "doc",
  "content": [
    {
      "type": "heading",
      "attrs": {
        "level": 1,
        "textAlign": null
      },
      "content": [
        {
          "text": "Dolutegravir: A Second-Generation Integrase Inhibitor for HIV Treatment",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "Abstract",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "orderedList",
      "attrs": {
        "type": null,
        "start": 1
      },
      "content": [
        {
          "type": "listItem",
          "content": [
            {
              "type": "paragraph",
              "attrs": {
                "textAlign": null
              },
              "content": [
                {
                  "text": "Human Immunodeficiency Virus continues ",
                  "type": "text"
                },
                {
                  "type": "math",
                  "attrs": {
                    "latex": "x = \\frac{-b \\pm \\sqrt{b^2 - 4ac}}{2a}"
                  }
                },
                {
                  "text": " to be a major global health challenge despite significant advances in antiretroviral therapy. Dolutegravira second-generation integrase strand transfer inhibitor has become a key component of modern HIV treatment regimens. This paper reviews the mechanism of action, pharmacokinetics, clinical efficacy, and safety profile of dolutegravir. Evidence from clinical trials demonstrates that DTG provides potent viral suppression, a high barrier to resistance, and favorable tolerability compared with earlier therapies.",
                  "type": "text"
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "1. Introduction",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Since the discovery of HIV, antiretroviral therapy has significantly improved the life expectancy of people living with HIV. Modern ART aims to suppress viral replication and prevent disease progression. Integrase inhibitors are a critical class of drugs because they target the HIV integrase enzyme responsible for inserting viral DNA into host cells ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Everett M. Rogers et al., 2019)",
            "status": "resolved",
            "citationId": "4ca82fce-4068-4b20-896c-151b08618f6a"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Everett M. Rogers et al., 2019)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Dolutegravir is a second-generation integrase inhibitor that is widely used in first-line HIV treatment regimens. Its high potency, once-daily dosing, and improved resistance profile distinguish it from earlier therapies ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Kenneth J. Livak & Thomas D. Schmittgen, 2001)",
            "status": "resolved",
            "citationId": "0331a21e-d16c-4de0-8eb8-a34c17cb18b7"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Kenneth J. Livak & Thomas D. Schmittgen, 2001)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "2. Mechanism of Action",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Dolutegravir inhibits the ",
          "type": "text"
        },
        {
          "text": "HIV-1 integrase enzyme",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": ", which is responsible for integrating viral DNA into the host cell genome. By blocking the strand transfer step of viral DNA integration, dolutegravir prevents viral replication and the formation of new infected cells ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Franz Faul et al., 2007)",
            "status": "resolved",
            "citationId": "b3448176-676c-4dd5-b601-b00905773f4c"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Franz Faul et al., 2007)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Compared with earlier integrase inhibitors such as raltegravir, dolutegravir demonstrates stronger binding to the integrase-DNA complex and a slower dissociation rate, resulting in improved antiviral activity and a higher barrier to resistance ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Kenneth J. Livak & Thomas D. Schmittgen, 2001)",
            "status": "resolved",
            "citationId": "0331a21e-d16c-4de0-8eb8-a34c17cb18b7"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Kenneth J. Livak & Thomas D. Schmittgen, 2001)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "3. Pharmacokinetics",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Dolutegravir is administered orally and is rapidly absorbed in the body, reaching peak plasma concentration within 2–3 hours. The drug has a half-life of approximately 14 hours, enabling convenient once-daily dosing ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Everett M. Rogers et al., 2019)",
            "status": "resolved",
            "citationId": "4ca82fce-4068-4b20-896c-151b08618f6a"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Everett M. Rogers et al., 2019)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "The drug is primarily metabolized through ",
          "type": "text"
        },
        {
          "text": "UGT1A1-mediated glucuronidation",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": ", with minor metabolism via the ",
          "type": "text"
        },
        {
          "text": "CYP3A4 pathway",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": ". This metabolic profile results in relatively few drug–drug interactions compared with older antiretroviral medications ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Berk Hess et al., 2008)",
            "status": "resolved",
            "citationId": "acef0587-7d1f-4c2b-94cf-32cdd2e3d492"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Berk Hess et al., 2008)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "4. Clinical Efficacy",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Clinical trials have demonstrated the strong antiviral efficacy of dolutegravir-based therapies.",
          "type": "text"
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "The ",
          "type": "text"
        },
        {
          "text": "SPRING-2 trial",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": " compared dolutegravir with raltegravir in treatment-naïve HIV-1 patients and found comparable rates of viral suppression after 48 weeks of treatment ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Michel de Certeau, 2000)",
            "status": "resolved",
            "citationId": "b65fe27c-d323-410a-b9df-61934eac312c"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Michel de Certeau, 2000)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Additionally, the ",
          "type": "text"
        },
        {
          "text": "SAILING trial",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": " showed that dolutegravir achieved higher viral suppression rates than raltegravir in treatment-experienced patients with resistance to other antiretroviral drugs ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(M. Shoji & LHD Experiment Group, 2020)",
            "status": "resolved",
            "citationId": "2ef306bf-ee8d-428b-8c6f-d8a820fbb02b"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(M. Shoji & LHD Experiment Group, 2020)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Studies such as the ",
          "type": "text"
        },
        {
          "text": "VIKING-4 trial",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": " have also shown that dolutegravir retains antiviral activity against HIV strains resistant to earlier integrase inhibitors ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(OliverH. Lowry et al., 1951)",
            "status": "resolved",
            "citationId": "24f229d1-0608-4028-a517-cffd4f4da5a9"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(OliverH. Lowry et al., 1951)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "5. Safety and Tolerability",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Dolutegravir is generally well tolerated among patients. Common side effects reported in clinical studies include headache, nausea, and insomnia. In most cases, adverse effects are mild and rarely lead to treatment discontinuation ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Kenneth J. Livak & Thomas D. Schmittgen, 2001)",
            "status": "resolved",
            "citationId": "0331a21e-d16c-4de0-8eb8-a34c17cb18b7"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Kenneth J. Livak & Thomas D. Schmittgen, 2001)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Some patients may experience a mild increase in serum creatinine levels due to inhibition of renal transporters, but this does not reflect actual impairment of kidney function ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Kenneth J. Livak & Thomas D. Schmittgen, 2001)",
            "status": "resolved",
            "citationId": "0331a21e-d16c-4de0-8eb8-a34c17cb18b7"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Kenneth J. Livak & Thomas D. Schmittgen, 2001)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "6. Resistance Profile",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "One of the most important advantages of dolutegravir is its ",
          "type": "text"
        },
        {
          "text": "high genetic barrier to resistance",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        },
        {
          "text": ". Resistance mutations occur rarely in treatment-naïve patients receiving dolutegravir-based therapy. Even when resistance mutations develop, they often reduce viral replication capacity, limiting further mutation development ",
          "type": "text"
        },
        {
          "type": "citation",
          "attrs": {
            "url": null,
            "text": "(Franz Faul et al., 2007)",
            "status": "resolved",
            "citationId": "b3448176-676c-4dd5-b601-b00905773f4c"
          }
        },
        {
          "text": ".",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(234, 88, 12, 0.22)",
                "ruleId": "BROKEN_REFERENCE",
                "message": "No matching reference found for citation \"(Franz Faul et al., 2007)\"",
                "expected": "Add the full reference to the bibliography section.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 2,
        "textAlign": null
      },
      "content": [
        {
          "text": "7. Conclusion",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      },
      "content": [
        {
          "text": "Dolutegravir has become a cornerstone of modern HIV therapy due to its potent antiviral activity, strong resistance profile, and favorable pharmacokinetics. Its effectiveness in both treatment-naïve and treatment-experienced patients has led to widespread adoption in global treatment guidelines. Continued research will further clarify its long-term safety and role in simplified HIV treatment regimens.",
          "type": "text"
        }
      ]
    },
    {
      "type": "horizontalRule"
    },
    {
      "type": "heading",
      "attrs": {
        "level": 1,
        "textAlign": null
      },
      "content": [
        {
          "text": "References (IEEE Format with Links)",
          "type": "text",
          "marks": [
            {
              "type": "bold"
            }
          ]
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": null,
        "url": "https://pubmed.ncbi.nlm.nih.gov/24524102/",
        "refText": "[1] Z. Temesgen, R. Talwani, and S. A. Rizza, “Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection,” Drugs Today, vol. 50, no. 1, pp. 7–14, 2014.https://pubmed.ncbi.nlm.nih.gov/24524102/",
        "citationId": "temp_1772955873293_e0ax9tzb5"
      },
      "content": [
        {
          "text": "[1] Z. Temesgen, R. Talwani, and S. A. Rizza, “Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection,” ",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(59, 130, 246, 0.18)",
                "ruleId": "FORMATTING_BRACKETS",
                "message": "Stray square brackets detected in non-IEEE reference.",
                "expected": "Verify if brackets are intentional or artifact from copy-paste.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        },
        {
          "text": "Drugs Today",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            },
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(59, 130, 246, 0.18)",
                "ruleId": "FORMATTING_BRACKETS",
                "message": "Stray square brackets detected in non-IEEE reference.",
                "expected": "Verify if brackets are intentional or artifact from copy-paste.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        },
        {
          "text": ", vol. 50, no. 1, pp. 7–14, 2014.",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(59, 130, 246, 0.18)",
                "ruleId": "FORMATTING_BRACKETS",
                "message": "Stray square brackets detected in non-IEEE reference.",
                "expected": "Verify if brackets are intentional or artifact from copy-paste.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        },
        {
          "type": "hardBreak",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(59, 130, 246, 0.18)",
                "ruleId": "FORMATTING_BRACKETS",
                "message": "Stray square brackets detected in non-IEEE reference.",
                "expected": "Verify if brackets are intentional or artifact from copy-paste.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        },
        {
          "text": "https://pubmed.ncbi.nlm.nih.gov/24524102/",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(59, 130, 246, 0.18)",
                "ruleId": "FORMATTING_BRACKETS",
                "message": "Stray square brackets detected in non-IEEE reference.",
                "expected": "Verify if brackets are intentional or artifact from copy-paste.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": null,
        "url": "https://pubmed.ncbi.nlm.nih.gov/24259658/",
        "refText": "[2] R. C. Rathbun, S. M. Lockhart, and M. M. Miller, “Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection,” Annals of Pharmacotherapy, vol. 48, no. 3, pp. 395–403, 2014.https://pubmed.ncbi.nlm.nih.gov/24259658/",
        "citationId": "temp_1772955873292_2rdmpyfwj"
      },
      "content": [
        {
          "text": "[2] R. C. Rathbun, S. M. Lockhart, an",
          "type": "text",
          "marks": [
            {
              "type": "citation-highlight",
              "attrs": {
                "url": null,
                "type": "originality",
                "color": "rgba(59, 130, 246, 0.18)",
                "ruleId": "FORMATTING_BRACKETS",
                "message": "Stray square brackets detected in non-IEEE reference.",
                "expected": "Verify if brackets are intentional or artifact from copy-paste.",
                "badgeCode": null,
                "similarity": 0,
                "sourceTitle": null,
                "aiProbability": 0
              }
            }
          ]
        },
        {
          "text": "d M. M. Miller, “Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection,” ",
          "type": "text"
        },
        {
          "text": "Annals of Pharmacotherapy",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            }
          ]
        },
        {
          "text": ", vol. 48, no. 3, pp. 395–403, 2014.",
          "type": "text"
        },
        {
          "type": "hardBreak"
        },
        {
          "text": "https://pubmed.ncbi.nlm.nih.gov/24259658/",
          "type": "text"
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": "10.1073/pnas.1011128107",
        "url": "https://doi.org/10.1073/pnas.1011128107",
        "refText": "[3] S. Hare et al., “Structural basis for functional tetramerization of lentiviral integrase,” Proceedings of the National Academy of Sciences, vol. 107, no. 46, pp. 19747–19752, 2010.https://doi.org/10.1073/pnas.1011128107",
        "citationId": "temp_1772955873290_s2ok9q60u"
      },
      "content": [
        {
          "text": "[3] S. Hare et al., “Structural basis for functional tetramerization of lentiviral integrase,” ",
          "type": "text"
        },
        {
          "text": "Proceedings of the National Academy of Sciences",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            }
          ]
        },
        {
          "text": ", vol. 107, no. 46, pp. 19747–19752, 2010.",
          "type": "text"
        },
        {
          "type": "hardBreak"
        },
        {
          "text": "https://doi.org/10.1073/pnas.1011128107",
          "type": "text"
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": "10.1128/AAC.00273-11",
        "url": "https://doi.org/10.1128/AAC.00273-11",
        "refText": "[4] S. Min et al., “Safety and pharmacokinetics of dolutegravir in HIV-infected subjects,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, pp. 3536–3542, 2011.https://doi.org/10.1128/AAC.00273-11",
        "citationId": "temp_1772955873287_8gyo0hlgp"
      },
      "content": [
        {
          "text": "[4] S. Min et al., “Safety and pharmacokinetics of dolutegravir in HIV-infected subjects,” ",
          "type": "text"
        },
        {
          "text": "Antimicrobial Agents and Chemotherapy",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            }
          ]
        },
        {
          "text": ", vol. 55, no. 9, pp. 3536–3542, 2011.",
          "type": "text"
        },
        {
          "type": "hardBreak"
        },
        {
          "text": "https://doi.org/10.1128/AAC.00273-11",
          "type": "text"
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": "10.1016/S0140-6736(12)61999-8",
        "url": "https://doi.org/10.1016/S0140-6736(12)61999-8",
        "refText": "[5] F. Raffi et al., “Once-daily dolutegravir versus raltegravir in treatment-naïve adults with HIV-1 infection,” The Lancet, vol. 381, no. 9868, pp. 735–743, 2013.https://doi.org/10.1016/S0140-6736(12)61999-8",
        "citationId": "temp_1772955873285_bktwc2ekn"
      },
      "content": [
        {
          "text": "[5] F. Raffi et al., “Once-daily dolutegravir versus raltegravir in treatment-naïve adults with HIV-1 infection,” ",
          "type": "text"
        },
        {
          "text": "The Lancet",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            }
          ]
        },
        {
          "text": ", vol. 381, no. 9868, pp. 735–743, 2013.",
          "type": "text"
        },
        {
          "type": "hardBreak"
        },
        {
          "text": "https://doi.org/10.1016/S0140-6736(12)61999-8",
          "type": "text"
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": "10.1016/S0140-6736(13)61221-0",
        "url": "https://doi.org/10.1016/S0140-6736(13)61221-0",
        "refText": "[6] P. E. Sax et al., “Dolutegravir versus raltegravir in antiretroviral-experienced adults with HIV-1 infection,” Lancet, 2013.https://doi.org/10.1016/S0140-6736(13)61221-0",
        "citationId": "temp_1772955873283_aeejvs56d"
      },
      "content": [
        {
          "text": "[6] P. E. Sax et al., “Dolutegravir versus raltegravir in antiretroviral-experienced adults with HIV-1 infection,” ",
          "type": "text"
        },
        {
          "text": "Lancet",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            }
          ]
        },
        {
          "text": ", 2013.",
          "type": "text"
        },
        {
          "type": "hardBreak"
        },
        {
          "text": "https://doi.org/10.1016/S0140-6736(13)61221-0",
          "type": "text"
        }
      ]
    },
    {
      "type": "bibliographyEntry",
      "attrs": {
        "doi": "10.1016/S1473-3099(13)70277-X",
        "url": "https://doi.org/10.1016/S1473-3099(13)70277-X",
        "refText": "[7] B. Grinsztejn et al., “Dolutegravir for integrase-inhibitor-resistant HIV-1 infection (VIKING-3 study),” Lancet Infectious Diseases, vol. 14, no. 2, pp. 129–135, 2014.https://doi.org/10.1016/S1473-3099(13)70277-X",
        "citationId": "temp_1772955873274_6eznusjpn"
      },
      "content": [
        {
          "text": "[7] B. Grinsztejn et al., “Dolutegravir for integrase-inhibitor-resistant HIV-1 infection (VIKING-3 study),” ",
          "type": "text"
        },
        {
          "text": "Lancet Infectious Diseases",
          "type": "text",
          "marks": [
            {
              "type": "italic"
            }
          ]
        },
        {
          "text": ", vol. 14, no. 2, pp. 129–135, 2014.",
          "type": "text"
        },
        {
          "type": "hardBreak"
        },
        {
          "text": "https://doi.org/10.1016/S1473-3099(13)70277-X",
          "type": "text"
        }
      ]
    },
    {
      "type": "paragraph",
      "attrs": {
        "textAlign": null
      }
    }
  ]
}